Plain-English translation of NCT05842330 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether methylphenidate (a common ADHD medication) can help people with ADHD who are currently incarcerated. Half of the 150 participants will receive the actual medication for three months, while the other half will receive a placebo (a pill with no active ingredient). All participants will also receive counseling and support during and after their time in prison.
ADHD is common in prison populations and often goes untreated, which can contribute to behavior problems and make it harder for people to stay out of the criminal justice system after release. This study aims to see whether treating ADHD early—while someone is still in prison—could be an effective, cost-saving way to reduce these risks.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the ADHD medication or a placebo pill taken daily for three months while you are in prison. The study doctor will check in with you weekly during the first month, then monthly afterward. You will also participate in a counseling program focused on cognitive and behavioral skills. Even after the three-month study period ends, you will be offered the option to continue treatment, and researchers will follow up with you for one year after your release to track your progress.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Switzerland
Phase
Large-scale testing
Sponsor
Stéphanie Baggio
Collaborators
University of Lausanne, University of Geneva, Switzerland
Enrollment target
~150 participants
Started
January 2024
Primary completion
October 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.